The AG10-501 ACT-EARLY study is a randomized, multicenter, double-blind, placebo-controlled study of acoramidis for prevention of ATTR (with specific reference to either its cardiomyopathic or polyneuropathic manifestations). Participants will be stratified at randomization.
The study population will be asymptomatic carriers of a known pathogenic TTR gene variant. A participant must be 18 to 75 inclusive years of age, and the age of the participant must be within 10 years younger than or older than the predicted age of disease onset (PADO) based either on family history (pedigree analysis) or, if family history is insufficient, based on a TTR Variant Actuarial table from published literature. For example, if PADO for a given individual is found to be 50 years, the age of the participant must be between 40 and 75 years inclusive.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥ 18 to ≤ 75 years of age inclusive.
Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M/p.V50M, V122I/p.V142I, T60A/p.T80A, or all other pathogenic TTR variants).
Participant's age is within 10 years younger than or older than PADO.
You may not be if
Evidence of ATTR-CM or ATTR-PN.
Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.
Contraindication to or inability to undergo cardiac magnetic resonance testing.
Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy
Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.
Major surgery within the past 3 months or planned during the next 12 months.